Burlington, Massachusetts, June 12, 2018 — Merck KGaA, Darmstadt, Germany, a leading science and technology company and leader in genome editing, today announced that The American Journal of Bioethics has accepted a novel publication on ethical issues in genome editing to be printed in its July issue. A summary version has been published in The American Journal of Bioethics’ blog.
“Publication of this work demonstrates that Merck KGaA, Darmstadt, Germany is a true ethical innovator,” said Udit Batra, member of the Executive Board and CEO, Life Science business of Merck KGaA, Darmstadt, Germany. “The company established a Bioethics Advisory Panel — a diverse group of global biomedical experts — to provide guidance for research in which its businesses are involved, including research on or using genome editing. We take this work very seriously.”
Co-authored by colleagues from the company’s Bioethics Advisory Panel, a diverse group of global biomedical experts, and colleagues from the company’s from Life Science and Healthcare businesses, the publication discusses the critical ethical issues involved with the practical processes of manufacture, sale and distribution of genome-editing technology products such as Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR).
“Our paper will enrich international deliberations about ethical issues in gene editing to incorporate the critical perspectives and responsibilities of suppliers,” said Jeremy Sugarman, the Harvey M. Meyerhoff professor of bioethics and medicine at the Johns Hopkins Berman Institute of Bioethics, and lead author of the publication. Sugarman is also a member of the Bioethics Advisory Panel.
“As a company that is leading the way in genome-editing innovation, Merck KGaA Darmstadt, Germany recognizes a need to develop and implement science-based bioethics,” said Steven Hildemann, global chief medical officer at the Healthcare business of Merck KGaA, Darmstadt Germany, and senior author of the publication. “This publication describes our novel approach to ensure our genome-editing products are developed and distributed adhering to the highest standards of rapidly evolving bioethical guidance.”
The company’s Bioethics Advisory Panel has defined a clear operational position taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.
A popular method of editing genes, CRISPR acts as genetic scissors which can be used to remove or replace an existing gene, switch a gene on or off or insert a new gene with unprecedented accuracy. The publication leverages MilliporeSigma’s experience in developing and selling CRISPR genome-editing technology over the past 13 years.
The Life Science business of Merck KGaA, Darmstadt, Germany has secured patents in Australia, Canada, China, Europe, Israel, Singapore and South Korea covering foundational CRISPR technology. Its CRISPR patents are directed to chromosomal integration, or cutting of the sequence of eukaryotic cells and insertion of a synthetic exogenous DNA sequence to make a desired genomic change. Scientists can replace a disease-associated mutation with a beneficial or functional sequence — important for creating disease models and allowing new gene therapy solutions.
The company has made significant contributions to the genome-editing field. It was the first to offer custom biomolecules for genome editing globally (TargeTron™ RNA-guided group II introns and CompoZr™ zinc finger nucleases), driving adoption of these techniques by researchers all over the world. MilliporeSigma was also the first to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.
An online preview of the genome-editing bioethics publication in The American Journal of Bioethics can be found at:
For more information on MiliporeSigma’s work in the genome-editing field, visit
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.